Bellicum Pharmaceuticals today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6 at 2:00 p.m. EDT in New York, NY.
Bellicum Pharmaceuticals today announced the appointment of Shane M. Ward as General Counsel and Corporate Secretary.
Moleculin today announced that its CEO, Walter Klemp, was asked to address the 2018 BioForum Conference in Łódź, Poland.
Bellicum announced that two abstracts on its lead product candidate BPX-501 have been selected for presentation at the 23rd Congress of the European Hematology Association.
Moleculin today announced that a second U.S. site, located in Lubbock, Texas, has qualified for its clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).
Bellicum announced that data of its HER2-targeted CAR-T cell will be reviewed in a presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapy.
Moleculin announced that it has engaged Voisin Consulting Life Sciences as an additional regulatory consulting firm and contract research organization.
LivaNova today announced it has successfully completed the divestiture of its Cardiac Rhythm Management business to MicroPort Scientific Corporation for $190 million in cash.